Vitamin Shoppe (VSI) Receiving Somewhat Positive Media Coverage, Analysis Finds

Share on StockTwits

Media headlines about Vitamin Shoppe (NYSE:VSI) have trended somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vitamin Shoppe earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the specialty retailer an impact score of 46.2391249462668 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Vitamin Shoppe remained flat at $$7.20 on Friday, according to Marketbeat Ratings. The stock had a trading volume of 3,509,016 shares, compared to its average volume of 547,819. The stock has a market cap of $174.47 million, a PE ratio of 18.46 and a beta of 0.51. The company has a current ratio of 1.88, a quick ratio of 0.44 and a debt-to-equity ratio of 0.47. Vitamin Shoppe has a 52 week low of $2.95 and a 52 week high of $12.00.

Vitamin Shoppe (NYSE:VSI) last released its earnings results on Wednesday, May 9th. The specialty retailer reported $0.10 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.10. The company had revenue of $295.96 million during the quarter, compared to analysts’ expectations of $293.44 million. Vitamin Shoppe had a positive return on equity of 1.28% and a negative net margin of 22.80%. sell-side analysts predict that Vitamin Shoppe will post -0.21 EPS for the current fiscal year.

A number of research analysts have recently commented on the company. ValuEngine upgraded Vitamin Shoppe from a “hold” rating to a “buy” rating in a research note on Tuesday, May 22nd. Morgan Stanley lowered their target price on Vitamin Shoppe from $4.00 to $3.75 and set an “equal weight” rating for the company in a research note on Wednesday, February 28th. Finally, Zacks Investment Research upgraded Vitamin Shoppe from a “sell” rating to a “hold” rating in a research note on Wednesday, May 16th. Four equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the company. The stock currently has an average rating of “Hold” and an average price target of $4.95.

In related news, Director Guillermo Marmol acquired 20,000 shares of the stock in a transaction on Friday, May 25th. The stock was acquired at an average price of $5.15 per share, for a total transaction of $103,000.00. Following the completion of the purchase, the director now owns 29,631 shares of the company’s stock, valued at $152,599.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Alex Smith acquired 12,666 shares of the stock in a transaction on Tuesday, May 29th. The shares were bought at an average price of $5.24 per share, with a total value of $66,369.84. Following the purchase, the chairman now directly owns 19,118 shares of the company’s stock, valued at approximately $100,178.32. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 190,053 shares of company stock valued at $805,158. 18.50% of the stock is currently owned by company insiders.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc, through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the United States and internationally. It operates in two segments, Retail and Manufacturing. The company provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.

Insider Buying and Selling by Quarter for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply